On products and services:
These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
THERMO FISHER SCIENTIFIC INC. (TMO) single-company analysis
This page is a descriptive assembly from a frozen evidence pack of public SEC filing excerpts and verified SEC companyfacts metrics. It is not a rating, recommendation, endorsement, forecast, valuation, or investment advice. Filer viewpoints are attributed to the filer and figures are as of their cited filing dates.
Informational only - not investment advice. See Disclaimer.
Back to TMO company profile. Existing company-page SVG figures remain the source for financial time-series context.
Business & segments
Financial profile
The values below are templated from verified SEC companyfacts-derived facts. The embedded SVG figures show selected annual series from the same facts.
Reported revenue: 44,556,000,000
Operating margin: 17.38%
Free cash flow: 6,293,000,000
Revenue scale is shown from verified SEC companyfacts. Revenue: 44,556,000,000
Operating margin is shown from verified SEC companyfacts. Operating margin: 17.38%
Net margin is shown from verified SEC companyfacts. Net margin: 15.05%
Free cash flow is computed from verified operating cash flow and capital expenditure facts. Free cash flow: 6,293,000,000
Capital expenditures are shown as reported payment magnitude from verified SEC companyfacts. Capital expenditures: 1,525,000,000
Dividends paid are shown as reported cash outflow magnitude from verified SEC companyfacts. Dividends paid: 636,000,000
| Metric | Value | Fiscal year | Period end | Source |
|---|---|---|---|---|
| Capital expenditures | 1,525,000,000 | 2025 | 2025-12-31 | USD |
| Dividends paid | 636,000,000 | 2025 | 2025-12-31 | USD |
| Free cash flow | 6,293,000,000 | 2025 | 2025-12-31 | USD |
| Net income | 6,704,000,000 | 2025 | 2025-12-31 | USD |
| Net margin | 15.05% | 2025 | 2025-12-31 | Percent |
| Operating cash flow | 7,818,000,000 | 2025 | 2025-12-31 | USD |
| Operating income | 7,746,000,000 | 2025 | 2025-12-31 | USD |
| Operating margin | 17.38% | 2025 | 2025-12-31 | Percent |
Stated strategy
Key idiosyncratic risks
On customer concentration or dependency:
Demand for some of our products depends on capital spending policies of our customers and on government funding policies.
Recent developments
On reported revenue movement:
Revenues in the academic and government market declined, driven by customer hesitancy in a more uncertain environment in the U.S. and macro conditions in China.
On operating-income movement:
GAAP operating income margin in 2025 also benefited from lower amortization expense when compared to 2024; however, this was partially offset by higher transaction-related costs.